Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension tags : License save search
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Buckreef Gold – Special Mining License Renewal Date Extension
Published: 2022-03-11 (Crawled : 12:30) - globenewswire.com
TRX | $0.4703 2.24% 2.06% 430K
|
Non-Energy Minerals
|
| O: 23.01%
H: 0.0%
C: 0.0%
license
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Published: 2021-09-24 (Crawled : 21:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
OPK | $1.23 0.0% 2.7M
|
Health Technology
| Email alert
Add to watchlist
fda growth hormone license growth hormone application
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Published: 2021-07-23 (Crawled : 16:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -5.13%
treatment lung cancer cancer antibody license
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Published: 2021-03-08 (Crawled : 04:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.38%
H: 0.76%
C: -4.25%
treatment lung cancer cancer antibody license phase 3 trial clearance
Silvercorp Receives Mining License Renewal and Extension
Published: 2021-02-09 (Crawled : 22:06) - globenewswire.com
SVM | $3.57 0.0% 1.4M
|
Non-Energy Minerals
|
| O: 1.6%
H: 0.0%
C: -2.52%
license
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Published: 2021-01-29 (Crawled : 13:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 9.91%
H: 0.66%
C: -4.01%
fda license alzheimer application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.